Walleye Capital
IGMS

Walleye Capital’s IGM Biosciences IGMS Stock Holding History

Walleye Capital’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,050
Closed -$193K – 5780
2024
Q1 		$193K Buy
+20,050
New +$232K ﹤0.01% 3996
2023
Q3 		– Sell
-69,417
Closed -$641K – 5077
2023
Q2 		$641K Buy
+69,417
New +$778K ﹤0.01% 2239
2022
Q1 		– Sell
-35,127
Closed -$1.03M – 2418
2021
Q4 		$1.03M Buy
+35,127
New +$1.75M 0.03% 576

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's IGMS Position: Q2 2024 in Review

Walleye Capital sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 20,050 shares — an estimated $193K sold.

Walleye Capital first reported a position in IGMS in Q4 2021 and held it in 3 quarters. The position peaked at $1.03M in Q4 2021. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

  • Walleye Capital reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 20,050 IGM Biosciences shares in Q2 2024, an estimated $193K.
  • Walleye Capital first reported a position in IGM Biosciences in Q4 2021 and held it in 3 quarters.
  • Walleye Capital's IGM Biosciences position peaked at $1.03M in Q4 2021.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.